This application is a divisional application of U.S. application Ser. No. 08/749,903, filed Nov. 15, 1996 (U.S. Pat. No. 5,759,812).
Entry |
---|
Knekt et al., “Serum Selenium and Subsequent Risk of Cancer Among Finnish Men and Women,” Journal of National Cancer Institute, 82,(10):864-868 (1990). |
Handel et al., “Inhibition of AP-1 binding and transcription by gold and selenium involving conserved cysteine residues in Jun and FOS,” Proc. Natl. Acad. Sci. USA, 97:4497-4501 (1995). |
Bansal, “DNA sequencing of a mouse liver protein that binds selenium: implications for selenium's mechanism of action in cancer prevention,” Carcinogenesis, 11(11):2071-2073 (1990) (GI 227630). |
Bartolone et al., “Purification, Antibody Production, and Partial Amino Acid Sequence of the 58-kDa Acetaminophen-Binding Liver Proteins,” Toxicology and Applied Pharmacology, 113:19-29 (1992). |
Lanfear et al., “Different patterns of regulation of the genes encoding the closely related 56 kDA selenium-and acetaminohen-binding proteins in normal tissues and during carcinogenesis,” Carcinogenesis, 14(3):335-340 (1993)(GI 298710). |
Ishii et al., “Significant induction of a 54-kDa protein in rat liver with homologous alignment to mouse binding protein by a coplanar polychlorinated bipheny1, 3, 4, 5, 3′, 4′-pentachlorobiphenyl and 3-methylcholanthrene,” Toxicology Letters, 87:1-9 (1996). |
Spyrou et al., “AP-1 DNA-binding activity is inhibited by selenite and selenodiglutathione,” FEBS Letters, 368:59-63 (1995). |
Morrison et al., “Intracellular 58-kd selenoprotein levels correlate with inhibition of DNA synthesis in mammary epithelial cells,” Carcinogenesis, 9(10):1801-1810 (1988). |
Chang et al., (GI 1374792), GenBank Sequence Database (Accession 1374792), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland 20894, Jun. 13, 1996. |